Enterprise Software
Omnicell
30-Second Executive Brief
Executive Assessment
Omnicell functions as an emerging institution within Enterprise Software, backed by 55% sourcing coverage, with a stable competitive position.
- Maintains 2 mapped relationships across the graph
- 55% sourcing coverage across sourced relationships
- Tracked as emerging institution within the Enterprise Software category
Executive Snapshot
- Strategic Role
- Emerging Institution
- Sourcing Coverage
- 55%
- Ecosystem Influence
- Regional
- Strategic Momentum
- Insufficient Data
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 2
- Technology Domains
- 3
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
Omnicell is a healthcare automation and pharmacy technology company providing medication management systems and software used by hospitals and pharmacies, anchored in a strategy of driving autonomous medication management via its cloud-native OmniSphere platform. Q1 2026 total revenue reached $310 million, up 15% year-over-year (20% product growth), with EPS beating estimates and non-GAAP EBITDA up 88%; the company booked its first Titan XT Automated Dispensing System orders in the quarter and maintained full-year 2026 revenue guidance of $1.215-1.255 billion.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
3 sources
- Omnicell corporate site — Omnicell corporate overviewcompany
- StockTitan / Benzinga — Omnicell Q1 2026 EPS beats forecast, raises full-year EBITDA and EPS guidancenews
- BusinessWire — Omnicell Q1 2026 revenue grows 15% to $310Mnews
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Omnicell — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Booking first orders for the Titan XT Automated Dispensing System in the same quarter EBITDA nearly doubled suggests hospital capital-equipment budgets are loosening for medication-automation upgrades, a useful signal for the broader healthcare-automation category given hospitals' historically cautious capex cycles
24% confidenceOne quarter of new-product order momentum is a modest data point, but combined with maintained full-year guidance rather than a cautious pullback, it's a reasonable early signal that Omnicell's next-generation dispensing hardware is gaining traction rather than facing budget resistance.
This is InsightNodes' own interpretive read connecting Omnicell's new-product order timing to broader hospital capex trends; the company's own release does not characterize the Titan XT orders as a budget-environment signal.
StockTitan / Benzinga · Aug 14, 2026